Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.

Noel N, Peña R, David A, Avettand-Fenoel V, Erkizia I, Jimenez E, Lecuroux C, Rouzioux C, Boufassa F, Pancino G, Venet A, Van Lint C, Martinez-Picado J, Lambotte O, Sáez-Cirión A, Prado JG.

J Virol. 2016 Jun 10;90(13):6148-6158. doi: 10.1128/JVI.00419-16. Print 2016 Jul 1.

2.

Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.

Noel N, Lerolle N, Lécuroux C, Goujard C, Venet A, Saez-Cirion A, Avettand-Fenoël V, Meyer L, Boufassa F, Lambotte O; ANRS C021 CODEX Study Group.

PLoS One. 2015 Jul 6;10(7):e0131922. doi: 10.1371/journal.pone.0131922. eCollection 2015.

3.

High Soluble CD14 Levels at Primary HIV-1 Infection Predict More Rapid Disease Progression.

Krastinova E, Lecuroux C, Leroy C, Seng R, Cabie A, Rami A, Venet A, Meyer L, Goujard C; ANRS PRIMO Cohort.

J Infect Dis. 2015 Sep 15;212(6):909-13. doi: 10.1093/infdis/jiv145. Epub 2015 Mar 6.

PMID:
25748321
4.

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group.

Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18.

PMID:
25701561
5.

High eomesodermin expression among CD57+ CD8+ T cells identifies a CD8+ T cell subset associated with viral control during chronic human immunodeficiency virus infection.

Simonetta F, Hua S, Lécuroux C, Gérard S, Boufassa F, Sáez-Cirión A, Pancino G, Goujard C, Lambotte O, Venet A, Bourgeois C.

J Virol. 2014 Oct;88(20):11861-71. doi: 10.1128/JVI.02013-14. Epub 2014 Aug 6.

6.

Potential role for HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppression and cytotoxicity in HIV controllers.

Hua S, Lécuroux C, Sáez-Cirión A, Pancino G, Girault I, Versmisse P, Boufassa F, Taulera O, Sinet M, Lambotte O, Venet A.

PLoS One. 2014 Jul 7;9(7):e101920. doi: 10.1371/journal.pone.0101920. eCollection 2014.

7.

Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients.

Noel N, Boufassa F, Lécuroux C, Saez-Cirion A, Bourgeois C, Dunyach-Remy C, Goujard C, Rouzioux C, Meyer L, Pancino G, Venet A, Lambotte O; ANRS C021 CODEX Study Group.

AIDS. 2014 Feb 20;28(4):467-76. doi: 10.1097/QAD.0000000000000174.

PMID:
24378753
8.

Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers.

Lécuroux C, Sáez-Cirión A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoël V, Rouzioux C, Meyer L, Pancino G, Lambotte O, Sinet M, Venet A.

J Virol. 2014 Jan;88(1):176-87. doi: 10.1128/JVI.02098-13. Epub 2013 Oct 16.

9.

High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers.

Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, Delfraissy JF, Saez-Cirion A, Ferrari G.

PLoS One. 2013 Sep 23;8(9):e74855. doi: 10.1371/journal.pone.0074855. eCollection 2013.

10.

Natural history of HIV-control since seroconversion.

Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; CASCADE Collaboration in Eurocoord.

AIDS. 2013 Sep 24;27(15):2451-60. doi: 10.1097/01.aids.0000431945.72365.01.

PMID:
23912979
11.

Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles.

Granier C, Battivelli E, Lécuroux C, Venet A, Lambotte O, Schmitt-Boulanger M, Delaugerre C, Molina JM, Chakrabarti LA, Clavel F, Hance AJ.

J Virol. 2013 Sep;87(18):10368-80. doi: 10.1128/JVI.01313-13. Epub 2013 Jul 17.

12.

CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection.

Lécuroux C, Girault I, Chéret A, Versmisse P, Nembot G, Meyer L, Rouzioux C, Pancino G, Venet A, Sáez-Cirión A; ANRS 147 OPTIPRIM clinical trial.

PLoS One. 2013;8(3):e59767. doi: 10.1371/journal.pone.0059767. Epub 2013 Mar 29.

13.

A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells.

Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, Chikata T, Kuse N, Fastenackels S, Gostick E, Bridgeman JS, Venturi V, Arkoub ZA, Agut H, van Bockel DJ, Almeida JR, Douek DC, Meyer L, Venet A, Takiguchi M, Rossjohn J, Price DA, Appay V.

Immunity. 2013 Mar 21;38(3):425-36. doi: 10.1016/j.immuni.2012.11.021.

14.

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group.

PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14.

15.

Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection.

Liovat AS, Rey-Cuillé MA, Lécuroux C, Jacquelin B, Girault I, Petitjean G, Zitoun Y, Venet A, Barré-Sinoussi F, Lebon P, Meyer L, Sinet M, Müller-Trutwin M.

PLoS One. 2012;7(10):e46143. doi: 10.1371/journal.pone.0046143. Epub 2012 Oct 2.

16.

NKG2D expression on HIV-specific CD8+ T cells is reduced in viremic HIV-1-infected patients but maintained in HIV controllers.

Lecuroux C, Saez-Cirion A, Noel N, Ben-Lamine L, Girault I, Caillat-Zucman S, Scott-Algara D, Venet A, Lambotte O.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):17-20. doi: 10.1097/QAI.0b013e318274579f.

17.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group.

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544
18.

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.

Goujard C, Emilie D, Roussillon C, Godot V, Rouzioux C, Venet A, Colin C, Pialoux G, Girard PM, Boilet V, Chaix ML, Galanaud P, Chene G; ANRS-112 INTERPRIM Study Group.

AIDS. 2012 Sep 24;26(15):1895-905.

PMID:
22842994
19.

Early and long-lasting alteration of effector CD45RA(-)Foxp3(high) regulatory T-cell homeostasis during HIV infection.

Simonetta F, Lecuroux C, Girault I, Goujard C, Sinet M, Lambotte O, Venet A, Bourgeois C.

J Infect Dis. 2012 May 15;205(10):1510-9. doi: 10.1093/infdis/jis235. Epub 2012 Mar 28.

20.

Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV.

Lévy Y, Thiébaut R, Gougeon ML, Molina JM, Weiss L, Girard PM, Venet A, Morlat P, Poirier B, Lascaux AS, Boucherie C, Sereni D, Rouzioux C, Viard JP, Lane C, Delfraissy JF, Sereti I, Chêne G; ILIADE Study Group.

AIDS. 2012 Mar 27;26(6):711-20. doi: 10.1097/QAD.0b013e3283519214.

PMID:
22301410
21.

CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory.

Boufassa F, Saez-Cirion A, Lechenadec J, Zucman D, Avettand-Fenoel V, Venet A, Rouzioux C, Delfraissy JF, Lambotte O, Meyer L; ANRS EP36 HIV Controllers Study Group.

PLoS One. 2011 Apr 21;6(4):e18726. doi: 10.1371/journal.pone.0018726.

22.

Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?

Goujard C, Chaix ML, Lambotte O, Deveau C, Sinet M, Guergnon J, Courgnaud V, Rouzioux C, Delfraissy JF, Venet A, Meyer L; Agence Nationale de Recherche sur le Sida PRIMO Study Group.

Clin Infect Dis. 2009 Sep 15;49(6):982-6. doi: 10.1086/605504.

PMID:
19681706
23.

Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells.

Lécuroux C, Girault I, Boutboul F, Urrutia A, Goujard C, Meyer L, Lambotte O, Chaix ML, Martinez V, Autran B, Sinet M, Venet A; ANRS PRIMO Cohort, ANRS HIC Study Group; ANRS ALT Cohort; ANRS HIC Study Group.

AIDS. 2009 Aug 24;23(13):1649-58. doi: 10.1097/QAD.0b013e32832e6634.

PMID:
19617814
24.

Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).

Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML, Venet A, Madelaine I, Sereni D, Jeanblanc F, Boulet T, Simon F, Aboulker JP; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 119 Interstart Study Team.

J Infect Dis. 2009 Jul 15;200(2):206-15. doi: 10.1086/599989.

PMID:
19508157
25.

Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses.

Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fènoël V, Rouzioux C, Delfraissy JF, Barré-Sinoussi F, Lambotte O, Venet A, Pancino G; ANRS EP36 HIV Controllers Study Group.

J Immunol. 2009 Jun 15;182(12):7828-37. doi: 10.4049/jimmunol.0803928.

26.

Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies.

Miceli-Richard C, Gestermann N, Amiel C, Sellam J, Ittah M, Pavy S, Urrutia A, Girauld I, Carcelain G, Venet A, Mariette X.

Arthritis Res Ther. 2009;11(3):R77. doi: 10.1186/ar2708. Epub 2009 May 26.

27.

Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection.

Lécuroux C, Girault I, Urrutia A, Doisne JM, Deveau C, Goujard C, Meyer L, Sinet M, Venet A.

Blood. 2009 Apr 2;113(14):3209-17. doi: 10.1182/blood-2008-07-167601. Epub 2008 Dec 19.

28.

Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts).

Seng R, Goujard C, Desquilbet L, Sinet M, Rouzioux C, Deveau C, Boufassa F, Delfraissy JF, Meyer L, Venet A; ANRS PRIMO and SEROCO Study Groups.

J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):251-8. doi: 10.1097/QAI.0b013e318189a739.

PMID:
18845951
29.

Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.

Adalid-Peralta L, Godot V, Colin C, Krzysiek R, Tran T, Poignard P, Venet A, Hosmalin A, Lebon P, Rouzioux C, Chene G, Emilie D; Interprim ANRS 112 Study Group.

J Leukoc Biol. 2008 Apr;83(4):1060-7. doi: 10.1189/jlb.1007675. Epub 2008 Jan 8.

30.

HIV controllers: how do they tame the virus?

Sáez-Cirión A, Pancino G, Sinet M, Venet A, Lambotte O; ANRS EP36 HIV CONTROLLERS study group.

Trends Immunol. 2007 Dec;28(12):532-40. Epub 2007 Nov 5. Review.

PMID:
17981085
31.

Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.

Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, Colle JH, Urrutia A, Scott-Algara D, Boufassa F, Delfraissy JF, Thèze J, Venet A, Chakrabarti LA.

J Virol. 2007 Dec;81(24):13904-15. Epub 2007 Oct 10.

32.

Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.

Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffrédy V, Venet A, Rouzioux C, Taoufik Y, El Habib R, Beumont-Mauviel M, Aboulker JP, Lévy Y, Delfraissy JF; PRIMOVAC-ANRS 095 Study Group.

AIDS Res Hum Retroviruses. 2007 Sep;23(9):1105-13.

PMID:
17919105
33.

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.

Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barré-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group.

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81. Epub 2007 Apr 11.

34.

Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.

Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, Sinet M, Tartour E, Aboulker JP, Autran B, Venet A; ANRS ELISpot Standardization Group.

Clin Vaccine Immunol. 2006 Jun;13(6):684-97.

35.

CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.

Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, Delfraissy JF, Venet A, Rouzioux C, Morlat P; Agence Nationale de Recherche sur le Sida PRIMO Study Group.

Clin Infect Dis. 2006 Mar 1;42(5):709-15. Epub 2006 Jan 24.

PMID:
16447119
36.

Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial.

Hoen B, Fournier I, Lacabaratz C, Burgard M, Charreau I, Chaix ML, Molina JM, Livrozet JM, Venet A, Raffi F, Aboulker JP, Rouzioux C; PRIMSTOP Study Group.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):307-16.

PMID:
16249705
37.

HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, Rouzioux C, Venet A, Delfraissy JF; SEROCO-HEMOCO Study Group.

Clin Infect Dis. 2005 Oct 1;41(7):1053-6. Epub 2005 Aug 30. Erratum in: Clin Infect Dis. 2005 Dec 1;41(11):1694. Clin Infect Dis. 2005 Sep 15;41 Suppl 6:1694.

PMID:
16142675
38.

Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells.

Anfossi N, Doisne JM, Peyrat MA, Ugolini S, Bonnaud O, Bossy D, Pitard V, Merville P, Moreau JF, Delfraissy JF, Dechanet-Merville J, Bonneville M, Venet A, Vivier E.

J Immunol. 2004 Dec 15;173(12):7223-9.

39.

Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort.

Schiffer V, Deveau C, Meyer L, Iraqui I, Nguyen-Wartel A, Chaix ML, Delfraissy JF, Rouzioux C, Venet A, Goujard C; French PRIMO Cohort Study Group.

HIV Med. 2004 Sep;5(5):326-33.

40.

CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection.

Doisne JM, Urrutia A, Lacabaratz-Porret C, Goujard C, Meyer L, Chaix ML, Sinet M, Venet A.

J Immunol. 2004 Aug 15;173(4):2410-8.

41.

Presence of HIV-specific CD4+ T-cell responses in HIV-infected subjects with sustained virologic control after highly active antiretroviral therapy.

Lacabaratz-Porret C, Viard JP, Goujard C, Lévy Y, Rodallec A, Deveau C, Venet A, Sinet M.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):594-9.

PMID:
15097302
42.

Delayed viral replication and CD4(+) T cell depletion in the rectosigmoid mucosa of macaques during primary rectal SIV infection.

Couëdel-Courteille A, Prétet JL, Barget N, Jacques S, Petitprez K, Tulliez M, Guillet JG, Venet A, Butor C.

Virology. 2003 Nov 25;316(2):290-301.

43.
44.

Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.

Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M.

J Infect Dis. 2003 Mar 1;187(5):748-57. Epub 2003 Feb 18.

PMID:
12599048
45.

Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.

Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, Sinet M, Delfraissy JF, Meyer L, Goujard C, Rouzioux C; Frnech PRIMO Cohort Study Group.

AIDS. 2001 Apr 13;15(6):665-73.

PMID:
11371680
46.

Longitudinal analysis of CD8(+) T-cell phenotype and IL-7, IL-15 and IL-16 mRNA expression in different tissues during primary simian immunodeficiency virus infection.

Caufour P, Le Grand R, Chéret A, Neildez O, Thiébot H, Théodoro F, Boson B, Vaslin B, Venet A, Dormont D.

Microbes Infect. 2001 Mar;3(3):181-91.

PMID:
11358712
47.

Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Dalod M, Dupuis M, Deschemin JC, Goujard C, Deveau C, Meyer L, Ngo N, Rouzioux C, Guillet JG, Delfraissy JF, Sinet M, Venet A.

J Clin Invest. 1999 Nov;104(10):1431-9.

48.

Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.

Hoen B, Dumon B, Harzic M, Venet A, Dubeaux B, Lascoux C, Bourezane Y, Ragnaud JM, Bicart-See A, Raffi F, Beauvais L, Fleury H, Séréni D.

J Infect Dis. 1999 Oct;180(4):1342-6.

PMID:
10479169
49.
50.

Dissemination of SIV after rectal infection preferentially involves paracolic germinal centers.

Couëdel-Courteille A, Butor C, Juillard V, Guillet JG, Venet A.

Virology. 1999 Aug 1;260(2):277-94.

Supplemental Content

Support Center